Lung Transplantation for Lymphangioleiomyomatosis: The French Experience
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lymphangioleiomyomatosis (LAM) is a rare disease, leading in some cases to end-stage respiratory failure. Lung transplantation (LT) represents a therapeutic option in advanced pulmonary LAM. METHODS: We conducted a retrospective multicenter study of 44 patients who underwent LT for LAM at 9 centers in France between 1988 and 2006. RESULTS: All patients were women with a mean age of 41+/-10 years at LT. There were 34 single-lung transplants and 11 bilateral transplants (one retransplantation). Prior clinical events related to LAM were present in 75% of the patients and previous thoracic surgical procedures were noted in 86.6% of cases. At the latest preoperative evaluation, 30 patients had an obstructive pattern (mean forced expiratory volume in 1 second: 26%+/-14% of predicted) and 15 had a combined restrictive and obstructive pattern, with a mean KCO=27%+/-8.8% of predicted, PaO2=52.8+/-10.4 and PaCO2=42.6+/-9.8 mm Hg. Intraoperative cardiopulmonary bypass was required in 13 cases. The length of mechanical ventilation was 7.5+/-12.8 days. The median duration of follow-up was 37 months. The 1, 2, 5, and 10 years survival rates were 79.6%, 74.4%, 64.7%, and 52.4%, respectively. Extensive pleural adhesions were found in 21 patients leading to severe intraoperative hemorrhage. Postoperative LAM-related complications were pneumothorax in the native lung in five patients, chylothorax in six, bronchial dehiscence or stenosis in seven. There were two cases of recurrence of LAM. CONCLUSION: Despite a high morbidity mainly caused by previous surgical interventions and disease-related complications, LT is a satisfactory therapeutic option for end-stage respiratory failure in LAM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Significant hemorrhage arising from angiomyolipomas is uncommon peri-operatively and their presence should not preclude candidacy for lung transplant.(311, 314)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [311]
In the citing paper
“Fewer patients with LAM have required lung transplant since the standardized use of mTOR inhibitors as treatment, but it remains an indication for those with severely abnormal lung function (FEV1 < 30%), exertional dyspnea (NYHA class III or IV), or hypoxemia at rest.(303–306, 308–315)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [311]
In the citing paper
“While disease recurrence does occur post-transplant, it does not appear to limit survival.(303, 304, 309, 311, 316–318)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [311]
Citations
Cites
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253 · cited 12×
“Although the recent published results of therapy with the mammalian target of rapamycin (mTOR) inhibitor, sirolimus hold promise especially as a treatment of angiomyolipoma (AML) (4), enthusiasm about the pulmonary function results should be tempered (5) and justify the need for larger clinical trials using such thera…”
BackgroundInfluentialOrens, J. B., Estenne, M., Arcasoy, S., Conte, J. V., Corris, P., Egan, J. J., Egan, T., Keshavjee, S., Knoop, C., Kotloff, R., et al. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2006.03.011 · Cited by 1,073
Trulock, E. P., Christie, J. D., Edwards, L. B., Boucek, M. M., Aurora, P., Taylor, D. O., Dobbels, F., Rahmel, A. O., Keck, B. M., & Hertz, M. I. (2007) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2007.06.003 · Cited by 485 · cited 6×
“In the 2007 registry of ISHLT (6), there were mostly bilateral procedures in LAM patients (59 SLT vs. 116 BLT).”
BackgroundInfluentialKitaichi, M., Nishimura, K., Itoh, H., & Izumi, T. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842216 · Cited by 362
Pulmonary Lymphangioleiomyomatosis: A Study of 69 Patients
Urban, T., Lazor, R., Lacronique, J., Murris, M., Labrune, S., & Valeyre, D. (1999) · Medicine · doi:10.1097/00005792-199909000-00004 · Cited by 329 · cited 1×
“It is characterized by respiratory symptoms such as dyspnea, cough, hemoptysis, but complications such as pneumothoraces or chylous effusions and ascitis can reveal the disease (2, 3).”
Recurrent Lymphangiomyomatosis after Transplantation: Genetic Analyses Reveal a Metastatic Mechanism
Karbowniczek, M., Astrinidis, A., Balsara, B. R., Testa, J. R., Lium, J. H., Colby, T. V., McCormack, F. X., & Henske, E. P. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-969oc · Cited by 254 · cited 2×
“Recent genetic analysis of these cases indicated that benign LAM cells migrate by metastatic mechanism to form new lesions in multiple organs and in the allograft (29).”
BackgroundLung Transplantation for Lymphangioleiomyomatosis
Boehler, A., Speich, R., Russi, E. W., & Weder, W. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610243351704 · Cited by 217
Sirolimus Therapy in Tuberous Sclerosis or Sporadic Lymphangioleiomyomatosis
Davies, D. M., Johnson, S. R., Tattersfield, A. E., Kingswood, J. C., Cox, J. A., McCartney, D. L., Doyle, T., Elmslie, F., Saggar, A., de Vries, P. J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmc072500 · Cited by 211 · cited 2×
“Although the recent published results of therapy with the mammalian target of rapamycin (mTOR) inhibitor, sirolimus hold promise especially as a treatment of angiomyolipoma (AML) (4), enthusiasm about the pulmonary function results should be tempered (5) and justify the need for larger clinical trials using such thera…”
BackgroundJohnson, S. R. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00113303 · Cited by 209
Lung Transplantation for Pulmonary Langerhans' Cell Histiocytosis: A Multicenter Analysis
Dauriat, G., Mal, H., Thabut, G., Mornex, J.-F., Bertocchi, M., Tronc, F., Leroy-Ladurie, F., Dartevelle, P., Reynaud-Gaubert, M., Thomas, P., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000200304.64613.af · Cited by 188 · cited 1×
“Like other systemic diseases such as Langerhans’ cell histiocytosis (24) and sarcoidosis (25), LAM could recur in the allograft but the recurrence rate seems to be much lower than for the other mentioned diseases.”
BackgroundSelf-citationManagement of Pneumothorax in Lymphangioleiomyomatosis
Almoosa, K. F., Ryu, J. H., Mendez, J., Huggins, J. T., Young, L. R., Sullivan, E. J., Maurer, J., McCormack, F. X., & Sahn, S. A. (2006) · Chest · doi:10.1378/chest.129.5.1274 · Cited by 159 · cited 3×
“Because experience with transplantation increased previous intrapleural interventions causing complexity of the operative dissection, and consecutive pleural-related perioperative bleeding became a relative than an absolute contraindication (8, 10, 18, 20).”
BackgroundBittmann, I., Rolf, B., Amann, G., & Löhrs, U. (2003) · Human Pathology · doi:10.1053/hupa.2003.50 · Cited by 141 · cited 1×
“Indeed, analysis of microsatellite markers revealed that foci of recurrent LAM in the allograft contain recipient-derived cells and that the same TCS2 gene mutation present in the native LAM cells was also found in the recurrent LAM cells, demonstrating that recurrent LAM foci did not represent neoformation of the tra…”
BackgroundTAVEIRA-DaSILVA, A. M., HEDIN, C., STYLIANOU, M. P., TRAVIS, W. D., MATSUI, K., FERRANS, V. J., & MOSS, J. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.6.2102125 · Cited by 130
The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis
Kpodonu, J., Massad, M. G., Chaer, R. A., Caines, A., Evans, A., Snow, N. J., & Geha, A. S. (2005) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2004.09.013 · Cited by 106
Lymphangioleiomyomatosis: recurrence after lung transplantation.
Nine, J. S., Yousem, S. A., Paradis, I. L., Keenan, R. J., & GRIFFITH, B. P. (1994) · PubMed · Cited by 103
Lymphangiomyomatosis recurrence in the allograft after single-lung transplantation.
O'Brien, J. D., Lium, J. H., Parosa, J. F., Deyoung, B. R., Wick, M. R., & Trulock, E. P. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.6.7767554 · Cited by 98
Lung transplantation for lymphangioleiomyomatosis
Pechet, T. T., Meyers, B. F., Guthrie, T. J., Battafarano, R. J., Trulock, E. P., Cooper, J. D., & Patterson, G. A. (2004) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(03)00195-5 · Cited by 77 · cited 9×
“(8) and the review of 14 patients who underwent LT for LAM in Washington University (10), the other published data on the topic have limitations largely because of the limitations of the registries (11, 12).”
BackgroundResultInfluentialLymphangioleiomyomatosis: Recurrence after single lung transplantation
Bittmann, I., Dose, T., Müller, C., Dienemann, H., Vogelmeier, C. F., & Löhrs, U. (1997) · Human Pathology · doi:10.1016/s0046-8177(97)90233-1 · Cited by 68
Lung Transplantation After Previous Thoracic Surgical Procedures
Detterbeck, F. C., Egan, T. M., & Mill, M. (1995) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(95)00324-x · Cited by 57 · cited 3×
“Because experience with transplantation increased previous intrapleural interventions causing complexity of the operative dissection, and consecutive pleural-related perioperative bleeding became a relative than an absolute contraindication (8, 10, 18, 20).”
BackgroundResultÜber muskuläre Cirrhose der Lunge
Stössel, E. (1937) · Lung · doi:10.1007/bf02142372 · Cited by 57
Lung Transplantation for Respiratory Failure Resulting From Systemic Disease
Pigula, F. A., Griffith, B. P., Zenati, M. A., Dauber, J. H., Yousem, S. A., & Keenan, R. J. (1997) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(97)00930-2 · Cited by 56 · cited 2×
“There are no specific data on the topic of immunosuppression in such patients, and transplanted LAM patients received the same immunosuppressive regimen than in other indications (10, 25).”
BackgroundPleural Disease in Lymphangioleiomyomatosis
Almoosa, K. F., McCormack, F. X., & Sahn, S. A. (2006) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2006.01.005 · Cited by 50 · cited 2×
“In the literature, the risk of pneumothorax occurring from the native lung after SLT and the occurrence of chylous effusions, sometimes recurrent and refractory chylothoraces, were also underlined in patients with LAM (8, 10, 15, 18, 19, 22).”
BackgroundMAURER, J. R., Ryu, J. H., Beck, G. J., Moss, J., Lee, J.-C., Finlay, G. A., Brown, K. K., Chapman, J. T., McMahan, J. L., Olson, E. J., et al. (2007) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2007.09.013 · Cited by 48 · cited 2×
“Our study gave us the opportunity to assess lung function before transplantation, data not reported by the registries (11, 12).”
BackgroundMethodPrevious intrapleural procedures do not adversely affect lung transplantation.
Dusmet, M. E., Winton, T. L., Kesten, S., & Maurer, J. (1996) · PubMed · Cited by 37
COMBINED HEART-AND-LUNG TRANSPLANTATION FOR LYMPHANGIOLEIOMYOMATOSIS
Estenne, M., Francquen, P. D., Wellens, F., LeClerc, J.-L., Vanderhoeft, P., Yernault, J. C., & Primo, G. C. (1984) · The Lancet · doi:10.1016/s0140-6736(84)90142-9 · Cited by 28
Fremont, R. D., Milstone, A. P., Light, R. W., & Ninan, M. (2007) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2007.07.008 · Cited by 26 · cited 1×
“In the literature, the risk of pneumothorax occurring from the native lung after SLT and the occurrence of chylous effusions, sometimes recurrent and refractory chylothoraces, were also underlined in patients with LAM (8, 10, 15, 18, 19, 22).”
BackgroundNephron-sparing nephrectomy for giant renal angiomyolipoma associated with lymphangioleiomyomatosis
HSU, T. H. S., O’Hara, J. F., Mehta, A. C., Levitin, A., & Klein, E. A. (2002) · Urology · doi:10.1016/s0090-4295(01)01505-9 · Cited by 25 · cited 1×
“A successful case of nephron-sparing nephrectomy after selective embolization for giant AML has been reported in a LAM transplanted women (23).”
BackgroundBoehler, A. (2001) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2001-18423 · Cited by 23
Collins, J., Müller, N. L., Kazerooni, E. A., McAdams, H. P., Leung, A. N., & Love, R. B. (1999) · Radiology · doi:10.1148/radiology.210.2.r99fe11325 · Cited by 22
Pollock‐BarZiv, S. M., Cohen, M. M., Maclean, H. M., & Downey, G. P. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.12.005 · Cited by 8 · cited 1×
“Finally, as we found in our cohort, despite there were demonstrably better pulmonary function test results in double lung transplant recipients (8, 17), there would be no differences in subjective measures of function using the Functional Performance Inventory scores between single and double lung recipients (17).”
Result
Cited by
Weill, D., Benden, C., Corris, P. A., Dark, J. H., Davis, R. D., Keshavjee, S., Lederer, D. J., Mulligan, M. J., Patterson, G. A., Singer, L. G., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.06.014 · Cited by 1,329
“If one includes prior chest tube insertion, the percentage of referred patients may be up to 40%(3,4) or for up to 90% in conditions such as lymphangioleiomyomatosis (LAM).(4) Surgery may be coincidental, for instance, previous CABG, but usually is related as a diagnostic or therapeutic step in pre-transplant manageme…”
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis
Johnson, S. R., Cordier, J. F., Lazor, R., Cottin, V., Costabel, U., Harari, S., Reynaud-Gaubert, M., Boehler, A., Brauner, M., Popper, H., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00076209 · Cited by 590
Self-citationGupta, N., Finlay, G. A., Kotloff, R. M., Strange, C., Wilson, K. C., Young, L. R., Taveira-DaSilva, A. M., Johnson, S. R., Cottin, V., Sahn, S. A., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201709-1965st · Cited by 253
“11) (44, 56, 57), and there was a trend toward such patients being more likely to have pleural adhesions (65% vs.”
BackgroundLung transplantation: indications and contraindications
Weill, D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.06.141 · Cited by 137
“There have been small series (14 and 18 patients) (5,6) describing successful lung transplant after chest surgery.”
BackgroundInfluential
Metadata
- Authors
- Reynaud-Gaubert, M., Mornex, J.-F., Mal, H., Treilhaud, M., Dromer, C., Quétant, S., Leroy-Ladurie, F., Guillemain, R., Philit, F., Dauriat, G., Grenet, D., & Stern, M.
- Affiliations
- Hôpital Louis Pradel (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Hôpital Albert Michallon (FR)
- Hôpital Marie Lannelongue (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Hôpital Foch (FR)
- Venue
- Transplantation
- Published
- 2008-08-27
- Volume
- 86
- Issue
- 4
- Pages
- 515-520
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2055288244
- Semantic Scholar
- 10f8cf3b79aa9476e25f53768ce8e3ca2933a97c
- Cited by
- 87
- References
- 30
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 7 · 2022: 9 · 2021: 4 · 2020: 6 · 2019: 4 · 2018: 5 · 2017: 5 · 2016: 3 · 2015: 8 · 2014: 5 · 2013: 5 · 2012: 4
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Transplantation (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lymphangioleiomyomatosis, lung transplantation, end-stage respiratory failure, postoperative complications, chylothorax, pneumothorax, bronchial stenosis, pleural adhesions, survival, bilateral lung transplantation, retransplantation
- MeSH terms
- Adult, Biopsy, Female, France, Histocompatibility Testing, Humans, Intraoperative Complications, Functional Laterality, Lung Neoplasms, Middle Aged, Oxygen Consumption, Surveys and Questionnaires, Respiratory Function Tests, Retrospective Studies, Smoking, Lung Transplantation, Treatment Outcome, Treatment Failure, Lymphangioleiomyomatosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.